Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Next Previous
Trial Profile

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Tafasitamab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms L-MIND
  • Sponsors MorphoSys

Most Recent Events

  • 26 Mar 2025 According to a Knight Therapeutics media release, company announced the launch of Minjuvi (tafasitamab) in Mexico by its Mexican affiliate. Marketing authorization approval was based on the data from L-MIND trial.
  • 29 Feb 2024 According to a Knight Therapeutics media release, company announced hat the launch of Minjuvi (tafasitamab) by Brazilian affiliate, United Medical Ltda. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, including DLBCL arising from low grade lymphoma, not eligible for autologous stem cell transplant (ASCT). The marketing authorization was based on the data from L-MIND study.
  • 16 Oct 2023 According to a Knight Therapeutics media release, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi (tafasitamab) from the Drugs Market Regulation Chamber based on the approval of data from L-MIND and company expects to launch Minjuvi in Brazil in the second quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top